Received May 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
| HEP | HEP B (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
| HEP | HEP B (NO BRAND NAME) | UNKNOWN MANUFACTURER | 3 | — | — |
did not have protective HBV antibody titers after 3 doses of HBV vaccine; This literature marketed report has been received from the authors of a published article, and refers to a 24-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions included obesity. Concomitant therapies were not reported. On unknown dates, the patient received the series of 3 vaccinations with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) (doses, route of administration, lot # and expiration dates were not reported) for prophylaxis. On an unknown date, the patient did not have protective HBV antibody titers after 3 doses of HBV vaccine. The outcome of the event was not reported. The reporter considered the event to be related to Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB). This is one of two cases derived from the same literature article (cross referenced with case# 2284106).
Medical History/Concurrent Conditions: Obesity
Test Name: Hepatitis B surface antibody; Test Result: Negative